Phase Ib trial of RP 5063 in healthy volunteers and patients with schizophrenia

Trial Profile

Phase Ib trial of RP 5063 in healthy volunteers and patients with schizophrenia

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Mar 2012

At a glance

  • Drugs RP 5063 (Primary)
  • Indications Schizoaffective disorder; Schizophrenia
  • Focus Adverse reactions
  • Most Recent Events

    • 14 Mar 2012 New trial record
    • 12 Mar 2012 Phase I study results will be presented at the New Clinical Drug Evaluation Unit (NCDEU) conference in 2012, according to a Reviva Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top